INCIDENCE, SEVERITY, AND TREATMENT OF COMMUNITY-ACQUIRED MRSA (CA-MRSA) SKIN AND SOFT TISSUE INFECTIONS (SSTI) IN 12 STARNet CLINICS:
Christopher R. Frei, PharmD, MSc, Michael L. Parchman, MD, MPH, Nicolas A. Forcade, PharmD, Liem C. Du, MD, Natalie R. Nyren, PA, Lucina Treviño, MD, Joel Peña, MD, Michael Mann, MD, Abilio Muñoz, MD, Sylvia Treviño, PA, Eric Mortensen, MD, MSc, Brian Wickes, PhD, Brad Pollock, PhD, James H. Jorgensen, PhD,

Setting:
Twelve primary care STARNet clinics participated in this prospective, community-based study.

Data Collection & Analysis:
Clinicians consented patients, collected clinical information, pictures, and wound swabs; data were processed centrally. MRSASelect™ was used for identification. Susceptibilities were determined for five antibiotics via Etest®.

Results:
80/135 (59%) patients had CA-MRSA;
Characteristics:
39/80 (49%) were male,
65/79 (82%) were Hispanic,
24/80 (30%) had diabetes, and
34/80 (43%) had a SSTI within the last 12 months.

Exam Findings:
Most (60/80, 75%) had abscesses;
38/60 (63%) abscesses were ≥5cm in diameter.
The majority of patients experienced pain scores of 7 or higher out of 10 (54/80, 68%).
Many presented with erythema (64/80, 80%),
drainage (43/80, 54%),
or ulceration (25/80, 31%).

Treatment
Most received incision and drainage plus an antibiotic (46/78, 60%).
78% Trimethoprim/sulfamethoxazole (TMP/SMX)
4% doxycycline
3% clindamycin
2% mupirocin

MRSA Antibiotic Sensitivity:
vancomycin (1.5 μg/mL, 100%),
doxycycline (0.047, 100%),
TMP/SMX (0.047, 100%), clindamycin (0.06, 94%), and
linezolid (1.0, 100%).

In conclusion, many patients presenting to medical clinics in Texas with SSTIs have CA-MRSA. Most of these patients receive incision and drainage plus anti-MRSA antibiotics.